Combined effects of systemic parathyroid hormone (1-34) and locally delivered neutral self-assembling peptide hydrogel in the treatment of periodontal defects: An experimental in vivo investigation.

Yoshida W, Matsugami D, Murakami T, Bizenjima T, Imamura K, Seshima F, Saito A

Journal of clinical periodontology1 Oct 2019Cited by 22 (Europe PMC)

PMID31292977DOI10.1111/jcpe.13170PepBankPUB-31292977

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

3 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Efficacy outcome
In rats with unfilled periodontal defects, systemic PTH increased bone volume versus saline at 2 weeks.
In plain wordsIn rats with unfilled periodontal defects, PTH increased bone volume compared with saline at 2 weeks.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseBone volume at two weeks
Study
ratn: not reported in source
Wistar rats with periodontal defects
Comparator
Saline in unfilled defects
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated
Source sentences
Summary
In vivo, systemic PTH resulted in significantly greater bone volume in the Unfilled group at 2 weeks (p = .01) and 4 weeks (p < .0001) than in the saline control.
2 context sentences(design, population, supporting numbers)
Summary · context
Periodontal defects were created mesially to the maxillary first molars in 40 Wistar rats.
Summary · context
Animals received PTH (1-34) or saline injections every 2 days.
Report a problemFND-3129297701
02AnimalAnimal study (in vivo)Efficacy outcome
In rats with unfilled periodontal defects, systemic PTH increased bone volume versus saline at 4 weeks.
In plain wordsIn rats with unfilled periodontal defects, PTH increased bone volume compared with saline at 4 weeks.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseBone volume at four weeks
Study
ratn: not reported in source
Wistar rats with periodontal defects
Comparator
Saline in unfilled defects
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated
Source sentences
Summary
In vivo, systemic PTH resulted in significantly greater bone volume in the Unfilled group at 2 weeks (p = .01) and 4 weeks (p < .0001) than in the saline control.
2 context sentences(design, population, supporting numbers)
Summary · context
Periodontal defects were created mesially to the maxillary first molars in 40 Wistar rats.
Summary · context
Animals received PTH (1-34) or saline injections every 2 days.
Report a problemFND-3129297702
03AnimalAnimal study (in vivo)Efficacy outcome
In rats with periodontal defects, PTH/SPG-178 increased bone volume compared with saline/SPG-178 at 4 weeks.
In plain wordsIn rats with periodontal defects, adding PTH to SPG-178 increased bone volume compared with saline/SPG-178 at 4 weeks.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseBone volume with SPG-178
Study
ratn: not reported in source
Wistar rats with periodontal defects
Comparator
Saline/SPG-178
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated
Source sentences
Summary
At 4 weeks, a significantly greater bone volume was observed in the PTH/SPG-178 (p = .0003) and PTH/Unfilled (p = .004) groups than in Saline/SPG-178 group.
2 context sentences(design, population, supporting numbers)
Summary · context
Periodontal defects were created mesially to the maxillary first molars in 40 Wistar rats.
Summary · context
Animals received PTH (1-34) or saline injections every 2 days.
Report a problemFND-3129297703

Studies that did not test the peptide alone5

In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Teriparatide (PTH 1-34).

04AnimalNot a test of Teriparatide (PTH 1-34) aloneAnimal study (in vivo)Efficacy outcome
In rats with periodontal defects, PTH with unfilled defects increased bone volume compared with saline/SPG-178 at 4 weeks.
In plain wordsIn rats, PTH with unfilled defects increased bone volume compared with saline/SPG-178 at 4 weeks.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseUnfilled defect bone volume versus saline hydrogel
Study
ratn: not reported in source
Wistar rats with periodontal defects
Comparator
Saline/SPG-178
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
At 4 weeks, a significantly greater bone volume was observed in the PTH/SPG-178 (p = .0003) and PTH/Unfilled (p = .004) groups than in Saline/SPG-178 group.
2 context sentences(design, population, supporting numbers)
Summary · context
Periodontal defects were created mesially to the maxillary first molars in 40 Wistar rats.
Summary · context
Animals received PTH (1-34) or saline injections every 2 days.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-3129297704
05AnimalNot a test of Teriparatide (PTH 1-34) aloneAnimal study (in vivo)Efficacy outcome
In rats with periodontal defects, PTH/SPG-178 showed greater bone formation than other groups at 4 weeks.
In plain wordsIn rats with periodontal defects, PTH/SPG-178 produced greater bone formation than other groups at 4 weeks.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseHistological bone formation
Study
ratn: not reported in source
Wistar rats with periodontal defects
Comparator
Other groups
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
Histologically, greater bone formation was observed in PTH/SPG-178 at 4 weeks than in other groups.
2 context sentences(design, population, supporting numbers)
Summary · context
Periodontal defects were created mesially to the maxillary first molars in 40 Wistar rats.
Summary · context
Animals received PTH (1-34) or saline injections every 2 days.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-3129297705
06AnimalNot a test of Teriparatide (PTH 1-34) aloneAnimal study (in vivo)Mechanism
In rats with periodontal defects, the PTH/SPG-178 group showed increased proportions of PCNA-positive cells at treated sites.
In plain wordsIn rats with periodontal defects, the PTH/SPG-178 group showed more PCNA-positive cells at treated sites.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreasePCNA-positive cells
Study
ratn: not reported in source
Wistar rats with periodontal defects
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
In the PTH/SPG-178 group, increased proportions of PCNA-, VEGF-, and Osterix-positive cells were observed in the treated sites.
2 context sentences(design, population, supporting numbers)
Summary · context
Periodontal defects were created mesially to the maxillary first molars in 40 Wistar rats.
Summary · context
Animals received PTH (1-34) or saline injections every 2 days.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-3129297706
07AnimalNot a test of Teriparatide (PTH 1-34) aloneAnimal study (in vivo)Mechanism
In rats with periodontal defects, the PTH/SPG-178 group showed increased proportions of VEGF-positive cells at treated sites.
In plain wordsIn rats with periodontal defects, the PTH/SPG-178 group showed more VEGF-positive cells at treated sites.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseVEGF-positive cells
Study
ratn: not reported in source
Wistar rats with periodontal defects
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
In the PTH/SPG-178 group, increased proportions of PCNA-, VEGF-, and Osterix-positive cells were observed in the treated sites.
2 context sentences(design, population, supporting numbers)
Summary · context
Periodontal defects were created mesially to the maxillary first molars in 40 Wistar rats.
Summary · context
Animals received PTH (1-34) or saline injections every 2 days.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-3129297707
08AnimalNot a test of Teriparatide (PTH 1-34) aloneAnimal study (in vivo)Mechanism
In rats with periodontal defects, the PTH/SPG-178 group showed increased proportions of Osterix-positive cells at treated sites.
In plain wordsIn rats with periodontal defects, the PTH/SPG-178 group showed more Osterix-positive cells at treated sites.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseOsterix-positive cells
Study
ratn: not reported in source
Wistar rats with periodontal defects
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
In the PTH/SPG-178 group, increased proportions of PCNA-, VEGF-, and Osterix-positive cells were observed in the treated sites.
2 context sentences(design, population, supporting numbers)
Summary · context
Periodontal defects were created mesially to the maxillary first molars in 40 Wistar rats.
Summary · context
Animals received PTH (1-34) or saline injections every 2 days.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-3129297708

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · source ClinicalTrials.gov (opens in a new tab)

Status unknownPhase 4NCT06061354

Teriparatide on Maxillary Sinus Floor Osseointegration

Universidad de Valparaison = 4223 Aug 2023 to est. Dec 2024

Bone Regeneration

Trial page ClinicalTrials.govUpdated 30 Nov 2023

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.